Anti-Vascular Endothelial Growth Factor (Bevacizumab) Therapy Reduces Hypertrophic Scar Formation in a Rabbit Ear Wounding Model

 

 Permissions and Reprints

Background Hypertrophic scarring is a pathological condition that occurs after trauma or surgery. Angiogenesis occurs more often with hypertrophic scarring than with normotrophic scarring. The regulation of angiogenesis is one of the key factors in hypertrophic scar management. Vascular endothelial growth factor (VEGF) is an essential factor in the angiogenetic response. This study investigated whether decreasing the level of VEGF is effective for treating hypertrophic scarring.

Methods Ten 8-week-old female New Zealand white rabbits were included. Four defects were created on each ear by using a 6-mm punch. Bevacizumab (Avastin, Roche Pharma, Basel, Switzerland) was administered in one ear and normal saline was administered in the other ear. Treatment was administered starting on day 2, every 2 days, until day 14. The levels of VEGF were measured using enzyme-linked immunosorbent assay on day 10 and histologic results were analyzed on day 40.

Results Bevacizumab induced-defects showed less hypertrophic scarring when compared with the control group as measured by the scar elevation index (SEI) and loose collagen arrangement. The SEI in the experimental group was 1.89±0.13, compared to 1.99±0.13 in the control group (n=30, P=0.005). Additionally, the VEGF level was lower (38.72±11.03 pg vs. 82.50±21.64 pg, n=10, P=0.001) and fewer vessels existed (8.58±0.76 vs. 7.2±1.20, n=10, P=0.007).

Conclusions Preventing excessive angiogenesis is effective for preventing scar formation, especially with hypertrophic scarring. Although it is not an approach that is sufficient alone for the management of scarring, it may be one of several important strategies for scar treatment.

Publication History

Received: 24 March 2016

Accepted: 31 August 2016

Article published online:
20 April 2022

© 2016. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 2010; 125: 557-568
  CrossrefPubMedGoogle Scholar
• 2 DiPietro LA. Angiogenesis and scar formation in healing wounds. Curr Opin Rheumatol 2013; 25: 87-91
  CrossrefPubMedGoogle Scholar
• 3 van der Veer WM, Niessen FB, Ferreira JA. et al. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen 2011; 19: 292-301
  CrossrefPubMedGoogle Scholar
• 4 Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000; 9: 413-418
  CrossrefPubMedGoogle Scholar
• 5 Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529
  CrossrefPubMedGoogle Scholar
• 6 Bock O, Schmid-Ott G, Malewski P. et al. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433-438
  CrossrefPubMedGoogle Scholar
• 7 Ong CT, Khoo YT, Tan EK. et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007; 211: 95-108
  CrossrefPubMedGoogle Scholar
• 8 Danese S. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol 2007; 23: 384-389
  CrossrefPubMedGoogle Scholar
• 9 Maruotti N, Cantatore FP, Crivellato E. et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21: 557-566
  PubMedGoogle Scholar
• 10 Nomoto H, Shiraga F, Kuno N. et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-4813
  CrossrefPubMedGoogle Scholar
• 11 Sinapis C, Routsias J, Sinapis D. et al. Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits. Invest Ophthalmol Vis Sci 2010; 51: 2440
  Google Scholar
• 12 Wang J, Chen H, Shankowsky HA. et al. Improved scar in postburn patients following interferon-alpha2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor. J Interferon Cytokine Res 2008; 28: 423-434
  CrossrefPubMedGoogle Scholar
• 13 Wilgus TA, Ferreira AM, Oberyszyn TM. et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008; 88: 579-590
  Google Scholar
• 14 Morris DE, Wu L, Zhao LL. et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg 1997; 100: 674-681
  CrossrefPubMedGoogle Scholar
• 15 Ko JH, Kim PS, Zhao Y. et al. HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model. Plast Reconstr Surg 2012; 129: 252e-262e
  CrossrefPubMedGoogle Scholar
• 16 Weidner N. Chapter 14. Measuring intratumoral microvessel density. Methods Enzymol 2008; 444: 305-323
  Google Scholar
• 17 Ren HT, Hu H, Li Y. et al. Endostatin inhibits hypertrophic scarring in a rabbit ear model. J Zhejiang Univ Sci B 2013; 14: 224-230
  CrossrefPubMedGoogle Scholar
• 18 Mello GR, Pizzolatti ML, Wasilewski D. et al. The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model. Clinics (Sao Paulo) 2011; 66: 1443-1450
  CrossrefPubMedGoogle Scholar